The treatment of major depressive disorders (MDD) in Thailand using escitalopram compared to fluoxetine and venlafaxine: A pharmacoeconomic evaluation

Journal of the Medical Association of Thailand

Volumn 91, Issue 7, 2008, Pages 1117-1128

  Kongsakon, Ronnachai ^a   Bunchapattanasakda, Chanchai ^b  

^a MAHIDOL UNIVERSITY   (Thailand)

^b SHINAWATRA UNIVERSITY   (Thailand)

Author keywords

Cost effectiveness; Escitalopram; Fluoxetine; Major depression; SNRI; SSRIs; Venlafaxine

Indexed keywords

AMITRIPTYLINE; ESCITALOPRAM; FLUOXETINE; LITHIUM; SERTRALINE; VENLAFAXINE;

ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG ACTIVITY; DRUG COST; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ELECTROCONVULSIVE THERAPY; HEALTH CARE COST; HEALTH CARE PERSONNEL; HEALTH CARE UTILIZATION; HEALTH SERVICE; HOSPITALIZATION; HUMAN; MAJOR DEPRESSION; PSYCHIATRIST; RATING SCALE; SENSITIVITY ANALYSIS; THAILAND; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CITALOPRAM; COST-BENEFIT ANALYSIS; CYCLOHEXANOLS; DECISION SUPPORT TECHNIQUES; DEPRESSIVE DISORDER, MAJOR; ECONOMICS, PHARMACEUTICAL; FLUOXETINE; FOCUS GROUPS; HUMANS; MODELS, THEORETICAL; PSYCHOMETRICS; SEROTONIN UPTAKE INHIBITORS; THAILAND;

EID: 48249099746     PISSN: 01252208     EISSN: 01252208     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. World Health Organization. Conquering depression: you can get out of the blues. New Delhi: Regional Office for South-East Asia, World Health Organization; 2001.
2. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ, editors. Global burden of disease and risk factors. New York: Oxford University Press; 2006.
3. National Collaborating Centre for Mental Health. Depression: management of depression in primary and secondary care [homepage on the Internet]. London: National Institute for Clinical Excellence (NICE); 2004 [cited 2008 Jul 3]. Available from: http://www.guideline.gov/browse/gawithdrawn.aspx?st=N
4. Kennedy SH, Lam RW, Cohen NL, Ravindran AV. Clinical guidelines for the treatment of depressive disorders. IV. Medications and other biological treatments. Can J Psychiatry 2001; 46(Suppl 1): 38S-58S.
5. American Psychiatric Association. American Psychiatric Association practice guidelines for the treatment of psychiatric disorders. Compendium 2006. Arlington, VA: American Psychiatric Association; 2006.
6. Statens Legemiddelverk, Norwegian Medicines Agency. Terapianbefaling: Farmakoterapi ved unipolar depresjon hos voksne og eldre [homepage on the Internet]. 2004 [cited 2008 Jul 3]. Available from: http://www.legemiddelverket. no/upload/76507/Depresjon%20voksne%20siste.pdf
7. Tarricone R, Fattore G, Gerzeli S, Serra G, Taddei C, Percudani M. The costs of pharmacological treatment for major depression. The Italian Prospective Multicentre Observational Incidence-Based Study. Pharmacoeconomics 2000; 17: 167-74.
8. Chen F, Larsen MB, Sanchez C, Wiborg O. The S-enantiomer of R, S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors. Eur Neuropsychopharmacol 2005; 15: 193-8.
9. Kennedy SH, Andersen HF, Lam RW. Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis. J Psychiatry Neurosci 2006; 31: 122-31.
10. Montgomery SA, Andersen HF. Escitalopram versus venlafaxine XR in the treatment of depression. Int Clin Psychopharmacol 2006; 21: 297-309.
11. Lam RW, Annemans L. Efficacy, effectiveness and efficiency of escitalopram in the treatment of major depressive and anxiety disorders. Expert Rev Pharmacoeconomics Outcomes Res 2007; 7: 559.
12. François C, Sintonen H, Toumi M. Introduction of escitalopram, a new SSRI in Finland: comparison of cost-effectiveness between the other SSRIs and SNRI for the treatment of depression and estimation of the budgetary impact. J Med Econ 2002; 5: 97-107.
13. Hemels ME, Kasper S, Walter E, Einarson TR. Cost-effectiveness analysis of escitalopram: a new SSRI in the first-line treatment of major depressive disorder in Austria. Curr Med Res Opin 2004; 20: 869-78.
14. Wade AG, Toumi I, Hemels ME. A probabilistic cost-effectiveness analysis of escitalopram, generic citalopram and venlafaxine as a first-line treatment of major depressive disorder in the UK. Curr Med Res Opin 2005; 21: 631-42.
15. Fernandez JL, Montgomery S, Francois C. Evaluation of the cost effectiveness of escitalopram versus venlafaxine XR in major depressive disorder. Pharmacoeconomics 2005; 23: 155-67.
16. Sorensen J, Stage KB, Damsbo N, Le Lay A, Hemels ME. A Danish cost-effectiveness model of escitalopram in comparison with citalopram and venlafaxine as first-line treatments for major depressive disorder in primary care. Nord J Psychiatry 2007; 61: 100-8.
17. Lançon C, Verpillat P, Annemans L, Despiegel N, François C. Escitalopram in major depressive disorder: clinical benefits and cost effectiveness versus citalopram. Int J Psychiatry Clin Pract 2007; 11: 44-52.
18. Patris M, Bouchard JM, Bougerol T, Charbonnier JF, Chevalier JF, Clerc G, et al. Citalopram versus fluoxetine: a double-blind, controlled, multicentre, phase III trial in patients with unipolar major depression treated in general practice. Int Clin Psychopharmacol 1996; 11: 129-36.
19. Francois C, Toumi M, Aakhus AM, Hansen K. A pharmacoeconomic evaluation of escitalopram, a new selective serotonin reuptake inhibitor. Comparison of cost-effectiveness between escitalopram, citalopram, fluoxetine, and venlafaxine for the treatment of depression in Norway. Eur J Health Econ 2003; 4: 12-9.
20. Rapaport MH, Bose A, Zheng H. Escitalopram continuation treatment prevents relapse of depressive episodes. J Clin Psychiatry 2004; 65: 44-9.
21. Gorwood P, Weiller E, Lemming O, Katona C. Escitalopram prevents relapse in older patients with major depressive disorder. Am J Geriatr Psychiatry 2007; 15: 581-93.
22. Robert P, Montgomery SA. Citalopram in doses of 20-60 mg is effective in depression relapse prevention: a placebo-controlled 6 month study. Int Clin Psychopharmacol 1995; 10(Suppl 1): 29-35.
23. Montgomery SA, Rasmussen JG, Tanghoj P. A 24-week study of 20 mg citalopram, 40 mg citalopram, and placebo in the prevention of relapse of major depression. Int Clin Psychopharmacol 1993; 8: 181-8.
24. Klysner R, Bent-Hansen J, Hansen HL, Lunde M, Pleidrup E, Poulsen DL, et al. Efficacy of citalopram in the prevention of recurrent depression in elderly patients: placebo-controlled study of maintenance therapy. Br J Psychiatry 2002; 181: 29-35.
25. Einarson TR. Evidence based review of escitalopram in treating major depressive disorder in primary care. Int Clin Psychopharmacol 2004; 19: 305-10.
26. Simon JS, Aguiar LM, Kunz NR, Lei D. Extended-release venlafaxine in relapse prevention for patients with major depressive disorder. J Psychiatr Res 2004; 38: 249-57.
27. Posternak MA, Zimmerman M. Switching versus augmentation: a prospective, naturalistic comparison in depressed, treatment-resistant patients. J Clin Psychiatry 2001; 62: 135-42.
28. Mulder RT, Joyce PR, Frampton CM, Luty SE, Sullivan PF. Six months of treatment for depression: outcome and predictors of the course of illness. Am J Psychiatry 2006; 163: 95-100.
29. Khan A, Khan SR, Leventhal RM, Brown WA. Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: a replication analysis of the Food and Drug Administration Database. Int J Neuropsychopharmacol 2001; 4: 113-8.
30. Ministry of Labour Thailand. The announcement of the Ministry of Labour on the minimum wage (issue 7): Minimum daily wage rate. Bangkok: Ministry of Labour Thailand; October 30, 2006.
31. Metropolis N, Ulam S. The Monte Carlo method. J Am Stat Assoc 1949; 44: 335-41.
32. Fantino B, Moore N, Verdoux H, Auray JP. Cost-effectiveness of escitalopram vs. citalopram in major depressive disorder. Int Clin Psychopharmacol 2007; 22: 107-15.
33. Löthgren M, Hemels ME, François C, Jönsson B. A cost-effectiveness analysis of escitalopram as first line treatment of depression in Sweden. Primary care psychiatry 2004; 9: 151-61.
34. th Annual Meeting of the Scandinavian College of Neuropsychopharmacology. Helsingør, Denmark, 27-30 April 2005.
35. Demyttenaere K, Hemels ME, Hudry J, Annemans L. A cost-effectiveness model of escitalopram, citalopram,and venlafaxine as first-line treatment for major depressive disorder in Belgium. Clin Ther 2005; 27: 111-24.